235 related articles for article (PubMed ID: 23571473)
1. Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer.
Berry MF; Worni M; Pietrobon R; D'Amico TA; Akushevich I
J Thorac Oncol; 2013 Jun; 8(6):744-52. PubMed ID: 23571473
[TBL] [Abstract][Full Text] [Related]
2. The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.
Duan H; Liang L; Xie S; Wang C
BMC Cancer; 2020 Aug; 20(1):809. PubMed ID: 32847544
[TBL] [Abstract][Full Text] [Related]
3. The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer.
Sawabata N; Keller SM; Matsumura A; Kawashima O; Hirono T; Osaka Y; Maeda H; Fukai S; Kawahara M;
Lung Cancer; 2003 Oct; 42(1):69-77. PubMed ID: 14512190
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
[TBL] [Abstract][Full Text] [Related]
5. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
6. A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy.
Han H; Zhao Y; Gao Z; Zheng D; Fu F; Zhao Z; Tang Y; Xiang J; Sun Y; Hu H; Chen H
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2115-2122. PubMed ID: 31175463
[TBL] [Abstract][Full Text] [Related]
7. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.
Choi NC; Carey RW; Daly W; Mathisen D; Wain J; Wright C; Lynch T; Grossbard M; Grillo H
J Clin Oncol; 1997 Feb; 15(2):712-22. PubMed ID: 9053497
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
9. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group.
Johnstone DW; Byhardt RW; Ettinger D; Scott CB
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):365-9. PubMed ID: 12243809
[TBL] [Abstract][Full Text] [Related]
10. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
[TBL] [Abstract][Full Text] [Related]
11. National patterns of care and outcomes after combined modality therapy for stage IIIA non-small-cell lung cancer.
Patel AP; Crabtree TD; Bell JM; Guthrie TJ; Robinson CG; Morgensztern D; Colditz GA; Kreisel D; Krupnick AS; Bradley JD; Patterson GA; Meyers BF; Puri V
J Thorac Oncol; 2014 May; 9(5):612-21. PubMed ID: 24722151
[TBL] [Abstract][Full Text] [Related]
12. Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancer.
Chen F; Okubo K; Sonobe M; Shibuya K; Matsuo Y; Kim YH; Yanagihara K; Bando T; Date H
World J Surg; 2012 Dec; 36(12):2858-64. PubMed ID: 22926283
[TBL] [Abstract][Full Text] [Related]
13. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
[TBL] [Abstract][Full Text] [Related]
14. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
Xu YP; Li B; Xu XL; Mao WM
Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
[TBL] [Abstract][Full Text] [Related]
15. [Impact of TNM staging and treatment mode on the prognosis of non-small cell lung cancer].
Yu DP; Bai LQ; Xu SF; Han M; Wang ZT
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):465-8. PubMed ID: 19950561
[TBL] [Abstract][Full Text] [Related]
16. Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer.
Li J; Dai CH; Yu LC; Chen P; Li XQ; Shi SB; Wu JR
Clin Lung Cancer; 2009 Sep; 10(5):353-9. PubMed ID: 19808194
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).
Nagai K; Tsuchiya R; Mori T; Tada H; Ichinose Y; Koike T; Kato H;
J Thorac Cardiovasc Surg; 2003 Feb; 125(2):254-60. PubMed ID: 12579093
[TBL] [Abstract][Full Text] [Related]
18. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
19. Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment.
Bonomi P; Gale M; Rowland K; Taylor SG; Purl S; Reddy S; Lee MS; Phillips A; Kittle CF; Warren W
Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):247-52. PubMed ID: 1846847
[TBL] [Abstract][Full Text] [Related]
20. Factors Associated With Treatment of Clinical Stage I Non-Small-cell Lung Cancer: A Population-based Analysis.
Berry MF; Canchola AJ; Gensheimer MF; Gomez SL; Cheng I
Clin Lung Cancer; 2018 Sep; 19(5):e745-e758. PubMed ID: 30149883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
